H. pylori  is the main cause of gastroduodenal diseases and is a common bacterial infection with more than 1.2 million annual new infections in the US alone. Most of the infected population are carriers and may not develop clinical complications from the infection but those that develop gastroduodenal diseases may suffer from peptic ulcers, gastric cancer, and mucosa-associated lymphoid tissue lymphomas (MALT). The increase in H. pylori prevalence is suspected to be correlated to the growing resistance of H. pylori to antibiotics.

Detection utilizing traditional methods tends to be time consuming, requires significant hands-on time and can be inaccurate due to an inability to test for more than a single strain, all of which makes this bacterium challenging to detect.

The use of multiplex real-time PCR-based technology allows for the simultaneous detection of multiple strains of H. pylori, increasing sensitivity and reducing turnaround time with fewer lab inefficiencies. This technology can specifically target more drug virulence or antibiotic resistance genes in a single test.

Novaplex™ H. pylori & ClariR Assay is a multiplex real-time PCR assay that detects and identifies H. pylori and the most frequent point mutations (A2142G, A2143G and A2142C) responsible for clarithromycin resistance within the H. pylori 23S rRNA gene. The kit utilizes stool or gastric biopsy specimens. With Novaplex H. pylori & ClariR Assays, users can conveniently detect H. pylori DNA in stool and perform PCR in a non-invasive way without the need for endoscopy.